All pages
Jump to navigation
Jump to search
- "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis"
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
- About OmniJournal
- Admin
- AmericasFrontlineDoctors
- AmericasFrontlineDoctorsPeerReview
- Americas Frontline Doctors
- Americas Frontline Doctors Peer Review
- An Effective Treatment for Coronavirus (COVID-19)
- COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
- COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
- Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
- Contact Us
- Create Page
- Disclaimers
- Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study.
- Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
- Early treatment with hydroxychloroquine: a country-randomized controlled trial
- Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
- Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
- Find More COVID-19 Papers
- Forty percent of people with coronavirus infections have no symptoms. Might they be the key to ending the pandemic
- Gilead: Twenty-one billion reasons to discredit hydroxychloroquine (ORIGINAL ARTICLE)
- Gilead: Twenty-one billion reasons to discredit hydroxychloroquine peer review
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier)
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial
- Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
- Main Page
- No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
- No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial
- Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
- Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
- Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
- Privacy Policy
- Privacy policy
- Risk Factors for Mortality in Patients with COVID-19 in New York City
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- Terms of Use
- Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients
- Treating COVID-19 with Chloroquine
- Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea
- Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
- Vitamin D deficiency causes a 10 times higher death rate in Covid-19 patients